Shi-Xian Gan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shi-Xian Gan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- David Wei Zhang
State Key Lab of ASIC & Systems, Fudan University, Shanghai 201203, China
4 shared publications - Hui Wang
Department of Chemistry, Fudan University, 2205 Songhu Road, Shanghai 200438, China
4 shared publications - Ru-Lei Zhang
Department of Chemistry, Fudan University, 2205 Songhu Road, Shanghai 200438, China
3 shared publications - Zhan-Ting Li
State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200032, China
3 shared publications - Congying Guo
Department of Chemistry, Fudan University, 2205 Songhu Road, Shanghai 200438, China
2 shared publications - Gang Zhao
School of Materials Science and Engineering
2 shared publications
Latest Publications
- 17 July 2026
- Published by Elsevier in Chinese Chemical Letters
- Vol. 38 (2)
Donor-acceptor interaction-driven inclusion of carbanions by molecular cage induces large pKa shifts of conjugate carbon acids in water
- 17 July 2026
- Published by Elsevier in Chinese Chemical Letters
- Vol. 38 (2)
Donor-acceptor interaction-driven inclusion of carbanions by molecular cage induces large pKa shifts of conjugate carbon acids in water
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13966-13979
Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs
Halogenation has been used as a useful strategy to optimize an imidazolium-based macrocyclic ultralong-acting neuromuscular blocking agent for improved bioactivity and biocompatibility. A structure–activity relationship study for 18 compounds reveals that monofluorinated macrocycle IMC-X5 displays blockade profiles generally superior to those of lead compound IMC-0. In vivo tests with a rat model show that, compared with those of IMC-0, the onset, profound blockade, and moderate blockade-to-spontaneous respiration times of IMC-X5 at the same dose of 0.2 mg/kg shortens by 47%, extends by 34%, and shortens by 89%, respectively, while the onset activity surpasses that of cisatracurium, one of the main neuromuscular blocking agents, of a clinically associated dose. Moreover, the profound blockade of IMC-X5 can be rapidly reversed by a biocompatible acyclic cucurbit[n]uril (ACB) antagonist at any stage of blockade. IMC-X5 also exhibits a biosafety superior to that of IMC-0. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13966-13979
Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs
Halogenation has been used as a useful strategy to optimize an imidazolium-based macrocyclic ultralong-acting neuromuscular blocking agent for improved bioactivity and biocompatibility. A structure–activity relationship study for 18 compounds reveals that monofluorinated macrocycle IMC-X5 displays blockade profiles generally superior to those of lead compound IMC-0. In vivo tests with a rat model show that, compared with those of IMC-0, the onset, profound blockade, and moderate blockade-to-spontaneous respiration times of IMC-X5 at the same dose of 0.2 mg/kg shortens by 47%, extends by 34%, and shortens by 89%, respectively, while the onset activity surpasses that of cisatracurium, one of the main neuromuscular blocking agents, of a clinically associated dose. Moreover, the profound blockade of IMC-X5 can be rapidly reversed by a biocompatible acyclic cucurbit[n]uril (ACB) antagonist at any stage of blockade. IMC-X5 also exhibits a biosafety superior to that of IMC-0. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.
- 31 March 2026
- Published by Elsevier in Chinese Chemical Letters
- Vol. 38 (1)
Anionic rectangular macrocyclic box enabling quantitative formation of mono- and dihydrazones in water through host-guest complexation
- 31 March 2026
- Published by Elsevier in Chinese Chemical Letters
- Vol. 38 (1)
Anionic rectangular macrocyclic box enabling quantitative formation of mono- and dihydrazones in water through host-guest complexation
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1752-1765
Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants
The development of a biocompatible antidote that can efficiently neutralize the anticoagulation activity of both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) represents an unmet medical need. Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction.
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1752-1765
Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants
The development of a biocompatible antidote that can efficiently neutralize the anticoagulation activity of both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) represents an unmet medical need. Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction.